Cardiovascular Effects of the New Weight Loss Agents

The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 68; no. 8; pp. 849 - 859
Main Authors Vorsanger, Matthew H., Subramanyam, Pritha, Weintraub, Howard S., Lamm, Steven H., Underberg, James A., Gianos, Eugenia, Goldberg, Ira J., Schwartzbard, Arthur Z.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 23.08.2016
Elsevier Limited
Subjects
Anti-Obesity Agents - pharmacology
Cardiology
Cardiovascular
cardiovascular disease
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
FDA approval
Health risk assessment
Humans
Life Style
Low density lipoprotein
Obesity
Obesity - complications
Obesity - drug therapy
pharmacology
prevention
Risk Factors
risk factors
SBP
cardiovascular disease
FDA
LDL-C
GLP
HR
HDL-C
POMC
pharmacology
hsCRP
risk factors
HbA1c
obesity
prevention
BMI
low-density lipoprotein cholesterol
high-sensitivity C-reactive protein
systolic blood pressure
glucagon-like peptide
high-density lipoprotein cholesterol
glycosylated hemoglobin
Food and Drug Administration
pro-opiomelanocortin
body mass index
HbA 1c
hazard ratio
Online AccessGet full text

Cover

Abstract The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
AbstractList The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
AbstractThe global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
Author Lamm, Steven H.
Weintraub, Howard S.
Schwartzbard, Arthur Z.
Underberg, James A.
Goldberg, Ira J.
Subramanyam, Pritha
Gianos, Eugenia
Vorsanger, Matthew H.
Author_xml – sequence: 1
  givenname: Matthew H.
  surname: Vorsanger
  fullname: Vorsanger, Matthew H.
  organization: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York
– sequence: 2
  givenname: Pritha
  surname: Subramanyam
  fullname: Subramanyam, Pritha
  organization: Division of General Internal Medicine, Department of Medicine, The Mount Sinai Hospital, New York, New York
– sequence: 3
  givenname: Howard S.
  surname: Weintraub
  fullname: Weintraub, Howard S.
  organization: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York
– sequence: 4
  givenname: Steven H.
  surname: Lamm
  fullname: Lamm, Steven H.
  organization: Division of General Internal Medicine, Department of Medicine, New York University Langone Medical Center, New York, New York
– sequence: 5
  givenname: James A.
  surname: Underberg
  fullname: Underberg, James A.
  organization: Division of General Internal Medicine, Department of Medicine, New York University Langone Medical Center, New York, New York
– sequence: 6
  givenname: Eugenia
  surname: Gianos
  fullname: Gianos, Eugenia
  organization: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York
– sequence: 7
  givenname: Ira J.
  surname: Goldberg
  fullname: Goldberg, Ira J.
  organization: Department of Medicine, Division of Endocrinology, New York University Langone Medical Center, New York, New York
– sequence: 8
  givenname: Arthur Z.
  surname: Schwartzbard
  fullname: Schwartzbard, Arthur Z.
  email: arthur.schwartzbard@nyumc.org
  organization: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27539178$$D View this record in MEDLINE/PubMed
BookMark eNqFklFrFDEUhYNU7Hb1D_ggA774smsySSaJiFCWqoVFH1R8DJnkps04O6nJTKX_3gzbUlhoCxeSh3POvflyT9DREAdA6DXBa4JJ875bd8badV3ua1wKi2doQTiXK8qVOEILLChfEazEMTrJucMYN5KoF-i4FpwqIuQCsY1JLsRrk-3Um1SdeQ92zFX01XgJ1Tf4V_2GcHE5VtuYc3V6AcOYX6Ln3vQZXt2eS_Tr89nPzdfV9vuX883pdmWZwmPp7KmChopG1M4SW7ccrPRN47hjmDIn29Yo713rOdSSYGElMcLxhtZWGUuX6N0-9yrFvxPkUe9CttD3ZoA4ZU0kqaVknNAifXsg7eKUhjLdrGKUKcZ4Ub25VU3tDpy-SmFn0o2-41EEci-wqTw3gdc2jGYMcRiTCb0mWM_odadn9HpGr3GpQnqJ6gPrXfqjpo97ExSM1wGSzjbAYMGFVP5Buxget386sNs-DMGa_g_cQL5HoHOtsf4xL8S8D6ShlDNBSsCHhwOe6v4fjh3Caw
CitedBy_id crossref_primary_10_3390_molecules28217381
crossref_primary_10_1056_NEJMoa1808721
crossref_primary_10_1159_000477742
crossref_primary_10_1016_j_jacc_2018_11_050
crossref_primary_10_2174_1871530319666181217123357
crossref_primary_10_1016_j_jacl_2024_04_001
crossref_primary_10_1161_CIRCRESAHA_119_315897
crossref_primary_10_3389_fendo_2019_00883
crossref_primary_10_1161_CIRCHEARTFAILURE_122_010453
crossref_primary_10_1016_j_mayocp_2019_05_021
crossref_primary_10_1016_j_pharmthera_2021_107866
crossref_primary_10_1093_ehjcvp_pvw029
crossref_primary_10_1007_s00221_020_05977_7
crossref_primary_10_3390_ijms23020847
crossref_primary_10_1007_s11906_017_0738_x
crossref_primary_10_1016_j_hipert_2016_10_001
crossref_primary_10_1038_s41591_024_03120_5
crossref_primary_10_1038_s41366_023_01321_5
crossref_primary_10_3389_fphar_2020_611361
crossref_primary_10_1007_s11883_021_00961_0
crossref_primary_10_1016_j_obpill_2024_100108
Cites_doi 10.1152/japplphysiol.01329.2010
10.1038/nn1455
10.1186/1471-244X-13-176
10.1016/j.diabres.2008.03.018
10.1056/NEJMoa1003114
10.1016/j.addbeh.2009.10.017
10.1161/CIRCRESAHA.116.305697
10.1038/oby.2002.142
10.1378/chest.09-0360
10.1001/jama.2016.1558
10.2337/dc14-0930
10.1056/NEJMoa1411892
10.1038/oby.2008.461
10.1002/oby.20309
10.1016/0361-9230(85)90115-7
10.1111/dme.12594
10.1093/ajcn/56.2.320
10.1016/j.amjcard.2005.03.053
10.2337/dc06-2001
10.1038/sj.ijo.0802783
10.1016/j.diabres.2014.01.019
10.1097/HCR.0000000000000112
10.1152/ajpendo.00030.2008
10.1016/S0140-6736(09)60659-0
10.1172/JCI75276
10.1586/14737175.8.5.715
10.1161/01.HYP.0000094221.86888.AE
10.2337/dc13-0234
10.1210/jc.2014-2291
10.3389/fnins.2013.00181
10.2337/dc08-2124
10.1111/j.1464-5491.2009.02666.x
10.1038/35078085
10.1176/appi.ajp.2007.07061018
10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3
10.1038/sj.ijo.0803382
10.1038/oby.2011.330
10.1038/oby.2003.102
10.1016/j.phrs.2014.04.004
10.1038/sj.npp.1300178
10.1016/S0899-9007(00)00452-4
10.1182/blood-2013-05-427708
10.2147/DMSO.S36276
10.1038/oby.2010.147
10.1038/oby.2001.71
10.2337/dc11-s220
10.3945/ajcn.111.024927
10.1016/S0140-6736(11)60205-5
10.2169/internalmedicine.52.8961
10.1038/ijo.2011.158
10.1056/NEJM199708283370901
10.1001/jama.2014.732
10.1210/jc.2009-1350
10.1016/S0168-8278(03)00172-7
10.1111/j.1753-4887.1997.tb06470.x
10.1016/j.gastro.2003.02.004
10.1038/ijo.2013.120
10.1007/s12020-015-0798-0
10.1016/j.ahj.2013.07.012
10.1186/s12902-015-0005-6
10.1007/s00592-013-0454-1
10.1038/nrendo.2009.48
10.1111/j.1467-789X.2007.00425.x
10.1007/s00125-009-1472-y
10.1016/S0140-6736(08)61246-5
10.1038/clpt.1985.197
10.1001/jama.2015.9676
10.1177/1479164111408937
10.1016/S0140-6736(10)60888-4
10.1038/sj.ijo.0802126
10.1161/CIRCULATIONAHA.113.006985
10.1097/JCP.0b013e318172424e
10.1177/0145721712443293
10.1136/bmj.1.5588.352
10.1111/dom.12012
10.1016/j.jacc.2013.11.004
10.1111/j.1471-4159.1993.tb05820.x
10.1016/j.addbeh.2007.05.012
10.1111/j.1463-1326.2006.00618.x
10.1136/bmj.d7771
10.2337/dc13-1518
10.1016/j.jdiacomp.2014.01.009
10.1056/NEJM199708283370904
10.1038/oby.2002.86
10.3390/nu5041218
10.1002/oby.20584
10.5665/sleep.2204
ContentType Journal Article
Copyright 2016 American College of Cardiology Foundation
American College of Cardiology Foundation
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Copyright Elsevier Limited Aug 23, 2016
Copyright_xml – notice: 2016 American College of Cardiology Foundation
– notice: American College of Cardiology Foundation
– notice: Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
– notice: Copyright Elsevier Limited Aug 23, 2016
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
H94
K9.
NAPCQ
7X8
DOI 10.1016/j.jacc.2016.06.007
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Neurosciences Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1558-3597
EndPage 859
ExternalDocumentID 4161300261
27539178
10_1016_j_jacc_2016_06_007
S0735109716335471
1_s2_0_S0735109716335471
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: P01 HL092969
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
18M
1B1
1P~
1~.
1~5
2WC
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
AABNK
AABVL
AAEDT
AAEDW
AAIKJ
AAOAW
AAQFI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABLJU
ABMAC
ABMZM
ABOCM
ACGFO
ACGFS
ACIUM
ACJTP
ACPRK
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFPUW
AFRAH
AFRHN
AFTJW
AGCQF
AGYEJ
AHMBA
AIGII
AITUG
AJRQY
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BLXMC
CS3
DIK
DU5
E3Z
EBS
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FNPLU
G-Q
GBLVA
GX1
H13
HVGLF
IHE
IXB
J1W
K-O
KQ8
L7B
MO0
N9A
O-L
O9-
OA.
OAUVE
OK1
OL~
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SSZ
TR2
UNMZH
UV1
W8F
WH7
WOQ
WOW
YYM
YZZ
Z5R
.55
.GJ
0SF
1CY
29L
3O-
3V.
6I.
7RV
AACTN
AAFTH
AAKUH
AALRI
AAQQT
AAQXK
AAYOK
ABVKL
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
AFCTW
AFETI
AFFNX
AGHFR
AJOXV
AMFUW
ASPBG
AVWKF
AZFZN
BENPR
BPHCQ
FGOYB
HX~
HZ~
J5H
N4W
NCXOZ
QTD
R2-
RIG
SEW
T5K
X7M
XPP
YYP
ZGI
ZXP
AAIAV
ABJNI
EFLBG
LCYCR
NAHTW
ZA5
AAYXX
AGQPQ
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c490t-10f39e637672dc1c2b5ec8f66d5d4034d8bba9ffdbf5e28107c81a7d5632c9ac3
IEDL.DBID IXB
ISSN 0735-1097
1558-3597
IngestDate Thu Jul 10 22:06:58 EDT 2025
Wed Aug 13 09:32:10 EDT 2025
Thu Apr 03 07:05:07 EDT 2025
Tue Jul 01 03:28:26 EDT 2025
Thu Apr 24 23:08:49 EDT 2025
Fri Feb 23 02:33:20 EST 2024
Sun Feb 23 10:19:05 EST 2025
Tue Aug 26 16:31:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords SBP
cardiovascular disease
FDA
LDL-C
GLP
HR
HDL-C
POMC
pharmacology
hsCRP
risk factors
HbA1c
obesity
prevention
BMI
low-density lipoprotein cholesterol
high-sensitivity C-reactive protein
systolic blood pressure
glucagon-like peptide
high-density lipoprotein cholesterol
glycosylated hemoglobin
Food and Drug Administration
pro-opiomelanocortin
body mass index
HbA 1c
hazard ratio
Language English
License This article is made available under the Elsevier license.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c490t-10f39e637672dc1c2b5ec8f66d5d4034d8bba9ffdbf5e28107c81a7d5632c9ac3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0735109716335471
PMID 27539178
PQID 1814349445
PQPubID 2031078
PageCount 11
ParticipantIDs proquest_miscellaneous_1812884513
proquest_journals_1814349445
pubmed_primary_27539178
crossref_citationtrail_10_1016_j_jacc_2016_06_007
crossref_primary_10_1016_j_jacc_2016_06_007
elsevier_sciencedirect_doi_10_1016_j_jacc_2016_06_007
elsevier_clinicalkeyesjournals_1_s2_0_S0735109716335471
elsevier_clinicalkey_doi_10_1016_j_jacc_2016_06_007
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-08-23
PublicationDateYYYYMMDD 2016-08-23
PublicationDate_xml – month: 08
  year: 2016
  text: 2016-08-23
  day: 23
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle Journal of the American College of Cardiology
PublicationTitleAlternate J Am Coll Cardiol
PublicationYear 2016
Publisher Elsevier Inc
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
References James, Caterson, Coutinho (bib14) 2010; 363
Jain, Kaplan, Gadde (bib59) 2002; 10
Dattilo, Kris-Etherton (bib104) 1992; 56
Felber, Golay (bib6) 2002; 26
Beilfuss L. Orexigen Terminates Required Study for Diet Drug Contrave. Wall Street Journal, May 12, 2015. Available at
Suzuki, Toyoda, Kimura (bib39) 2013; 52
Shukla, Buniak, Aronne (bib81) 2015; 35
Frier, Schernthaner, Heller (bib33) 2011; 34
Garvey, Ryan, Henry (bib100) 2014; 37
Wadden, Hollander, Klein (bib22) 2013; 37
Silverman E. Orexigen Data is 'Unreliable and Premature:' FDA's Jenkins Explains. The Wall Street Journal, March 6, 2015. Available at
Connolly, Crary, McGoon (bib16) 1997; 337
Sweeting, Tabet, Caterson (bib11) 2014; 7
Tek, Guloksuz, Srihari (bib66) 2013; 13
Wilcox, Oskooilar, Erickson (bib69) 2010; 35
Mark, Patalas, Chang (bib15) 1997; 337
Marso, Lindsey, Stolker (bib44) 2011; 8
Russell-Jones, Vaag, Schmitz (bib31) 2009; 52
Fonseca, Devries, Henry (bib35) 2014; 28
Kast, Altschuler (bib68) 2003; 39
Toll, Leary, Wu (bib70) 2008; 33
Malcolm, O'Neil, Sexauer (bib54) 1985; 9
(bib84) 2010
Gadde, Allison, Ryan (bib95) 2011; 377
Nissen, Wolski, Prcela (bib80) 2016; 315
Rosenstock, Hollander, Gadde (bib89) 2007; 30
Vilsbøll, Christensen, Junker (bib21) 2012; 344
Kahal, Aburima, Ungvari (bib40) 2015; 15
Gadde, Parker, Maner (bib60) 2001; 9
Maggio, Presta, Bracco (bib55) 1985; 14
(bib64) 2014
(bib48) 2010
Sun, Chai, Li (bib34) 2015; 2015
Tonstad, Tykarski, Weissgarten (bib92) 2005; 96
Wadden, Foreyt, Foster (bib13) 2011; 19
Smilowitz, Donnino, Schwartzbard (bib42) 2014; 129
Anderson, Greenway, Fujioka (bib58) 2002; 10
Zinman, Gerich, Buse (bib27) 2009; 32
Greenway, Fujioka, Plodkowski (bib63) 2010; 376
Bronstein, Day, Gutstein (bib52) 1993; 60
(bib25) 2014
Apovian, Aronne, Rubino (bib61) 2013; 21
Toplak, Hamann, Moore (bib91) 2007; 31
Sjoberg, Brinkworth, Wycherley (bib105) 2011; 110
Richard, Ferland, Lalonde (bib86) 2000; 16
Bray, Hollander, Klein (bib87) 2003; 11
Romero-Corral, Caples, Lopez-Jimenez (bib7) 2010; 137
Pontiroli, Merlotti, Veronelli (bib106) 2013; 50
Stenlöf, Rössner, Vercruysse (bib90) 2007; 9
Rösner, Hackl-Herrwerth, Leucht (bib72) 2010
Qsymia [package insert]. Mountain View, CA: Vivus, Inc.; 2012–2014.
Marso, Poulter, Nissen (bib46) 2013; 166
Nauck, Frid, Hermansen (bib30) 2013; 15
Husum, Van Kammen, Termeer (bib85) 2003; 28
Margulies K, Anstrom KJ, Redfield MM, et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). Paper presented at: American Heart Association Scientific Sessions; November 8, 2015; Orlando, FL.
Jensen, Ryan, Apovian (bib2) 2014; 63
Rizzo, Abate, Chandalia (bib41) 2015; 100
Billes, Sinnayah, Cowley (bib49) 2014; 84
Garvey, Ryan, Bohannon (bib99) 2014; 37
Winslow, Bowden, DiDonato (bib101) 2012; 35
McElroy, Guerdjikova, Kim (bib73) 2013; 15
Secher, Jelsing, Baquero (bib19) 2014; 124
Shantha, Kumar, Kahan (bib102) 2012; 38
(bib76) 2016
Jefferson (bib74) 2008; 8
(bib93) 2014
Hall, do Carmo, da Silva (bib4) 2015; 116
Chen, Shen, Zhang (bib43) 2016; 52
Thase, Haight, Johnson (bib65) 2008; 28
Ogden, Carroll, Kit (bib1) 2014; 311
von Scholten, Lajer, Goetze (bib36) 2015; 32
Cowley, Smart, Rubinstein (bib51) 2001; 411
Suter, Häsler, Vetter (bib71) 1997; 55
Seino, Rasmussen, Zdravkovic (bib26) 2008; 81
Allison, Gadde, Garvey (bib94) 2012; 20
Hollander, Gupta, Plodkowski (bib62) 2013; 36
Pi-Sunyer, Astrup, Fujioka (bib23) 2015; 373
Accessed June 13, 2016.
Aronne, Wadden, Peterson (bib97) 2013; 21
Garber, Henry, Ratner (bib28) 2009; 373
Lovshin, Drucker (bib17) 2009; 5
Greenway, Whitehouse, Guttadauria (bib53) 2009; 17
Cervera, Wajcberg, Sriwijitkamol (bib18) 2008; 294
Marre, Shaw, Brändle (bib29) 2009; 26
Skibicka (bib20) 2013; 7
Taylor, Dietrich, Powell (bib10) 2013; 6
Munro, MacCuish, Wilson (bib83) 1968; 1
Silverman E. Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data. Wall Street Journal, March 4, 2015. Available at
Drew, Dixon, Dixon (bib9) 2007; 3
Buse, Rosenstock, Sesti (bib32) 2009; 374
Wilding, Van Gaal, Rissanen (bib88) 2004; 28
Nakamura, Fuster, Walsh (bib3) 2014; 63
Klop, Elte, Cabezas (bib5) 2013; 5
Cone (bib50) 2005; 8
Garvey, Ryan, Look (bib96) 2012; 95
Kane, Altschuler, Kast (bib67) 2003; 125
Samad, Ruf (bib8) 2013; 122
Rothman, Baumann, Dersch (bib82) 2001; 39
Surtees, Wainwright, Luben (bib75) 2008; 165
Díaz-Soto, de Luis, Conde-Vicente (bib38) 2014; 104
Neter, Stam, Kok (bib103) 2003; 42
Florentin, Liberopoulos, Elisaf (bib37) 2008; 9
Greenway, Dunayevich, Tollefson (bib56) 2009; 94
Davies, Bergenstal, Bode (bib24) 2015; 314
Marso, Daniels, Brown-Frandsen (bib47) 2016 Jun 13
Atkinson, Berke, Drake (bib57) 1985; 38
Astrup, Carraro, Finer (bib12) 2012; 36
Hollander (10.1016/j.jacc.2016.06.007_bib62) 2013; 36
McElroy (10.1016/j.jacc.2016.06.007_bib73) 2013; 15
Klop (10.1016/j.jacc.2016.06.007_bib5) 2013; 5
Maggio (10.1016/j.jacc.2016.06.007_bib55) 1985; 14
Toll (10.1016/j.jacc.2016.06.007_bib70) 2008; 33
Tonstad (10.1016/j.jacc.2016.06.007_bib92) 2005; 96
Russell-Jones (10.1016/j.jacc.2016.06.007_bib31) 2009; 52
Marso (10.1016/j.jacc.2016.06.007_bib44) 2011; 8
von Scholten (10.1016/j.jacc.2016.06.007_bib36) 2015; 32
Zinman (10.1016/j.jacc.2016.06.007_bib27) 2009; 32
Cowley (10.1016/j.jacc.2016.06.007_bib51) 2001; 411
(10.1016/j.jacc.2016.06.007_bib64) 2014
Samad (10.1016/j.jacc.2016.06.007_bib8) 2013; 122
Jensen (10.1016/j.jacc.2016.06.007_bib2) 2014; 63
Wilding (10.1016/j.jacc.2016.06.007_bib88) 2004; 28
Hall (10.1016/j.jacc.2016.06.007_bib4) 2015; 116
Surtees (10.1016/j.jacc.2016.06.007_bib75) 2008; 165
Nakamura (10.1016/j.jacc.2016.06.007_bib3) 2014; 63
Astrup (10.1016/j.jacc.2016.06.007_bib12) 2012; 36
Sjoberg (10.1016/j.jacc.2016.06.007_bib105) 2011; 110
10.1016/j.jacc.2016.06.007_bib45
Garvey (10.1016/j.jacc.2016.06.007_bib99) 2014; 37
Taylor (10.1016/j.jacc.2016.06.007_bib10) 2013; 6
Richard (10.1016/j.jacc.2016.06.007_bib86) 2000; 16
Ogden (10.1016/j.jacc.2016.06.007_bib1) 2014; 311
Greenway (10.1016/j.jacc.2016.06.007_bib56) 2009; 94
Kane (10.1016/j.jacc.2016.06.007_bib67) 2003; 125
Buse (10.1016/j.jacc.2016.06.007_bib32) 2009; 374
Greenway (10.1016/j.jacc.2016.06.007_bib63) 2010; 376
(10.1016/j.jacc.2016.06.007_bib84) 2010
Gadde (10.1016/j.jacc.2016.06.007_bib60) 2001; 9
Gadde (10.1016/j.jacc.2016.06.007_bib95) 2011; 377
Díaz-Soto (10.1016/j.jacc.2016.06.007_bib38) 2014; 104
Jain (10.1016/j.jacc.2016.06.007_bib59) 2002; 10
Rosenstock (10.1016/j.jacc.2016.06.007_bib89) 2007; 30
Cone (10.1016/j.jacc.2016.06.007_bib50) 2005; 8
Lovshin (10.1016/j.jacc.2016.06.007_bib17) 2009; 5
Atkinson (10.1016/j.jacc.2016.06.007_bib57) 1985; 38
Marre (10.1016/j.jacc.2016.06.007_bib29) 2009; 26
Rösner (10.1016/j.jacc.2016.06.007_bib72) 2010
Felber (10.1016/j.jacc.2016.06.007_bib6) 2002; 26
Vilsbøll (10.1016/j.jacc.2016.06.007_bib21) 2012; 344
Marso (10.1016/j.jacc.2016.06.007_bib47) 2016
Greenway (10.1016/j.jacc.2016.06.007_bib53) 2009; 17
Husum (10.1016/j.jacc.2016.06.007_bib85) 2003; 28
Connolly (10.1016/j.jacc.2016.06.007_bib16) 1997; 337
Mark (10.1016/j.jacc.2016.06.007_bib15) 1997; 337
Aronne (10.1016/j.jacc.2016.06.007_bib97) 2013; 21
Malcolm (10.1016/j.jacc.2016.06.007_bib54) 1985; 9
(10.1016/j.jacc.2016.06.007_bib93) 2014
Florentin (10.1016/j.jacc.2016.06.007_bib37) 2008; 9
Allison (10.1016/j.jacc.2016.06.007_bib94) 2012; 20
Rizzo (10.1016/j.jacc.2016.06.007_bib41) 2015; 100
Thase (10.1016/j.jacc.2016.06.007_bib65) 2008; 28
Skibicka (10.1016/j.jacc.2016.06.007_bib20) 2013; 7
Garvey (10.1016/j.jacc.2016.06.007_bib96) 2012; 95
Smilowitz (10.1016/j.jacc.2016.06.007_bib42) 2014; 129
Munro (10.1016/j.jacc.2016.06.007_bib83) 1968; 1
10.1016/j.jacc.2016.06.007_bib77
Cervera (10.1016/j.jacc.2016.06.007_bib18) 2008; 294
Billes (10.1016/j.jacc.2016.06.007_bib49) 2014; 84
10.1016/j.jacc.2016.06.007_bib79
Shukla (10.1016/j.jacc.2016.06.007_bib81) 2015; 35
Wadden (10.1016/j.jacc.2016.06.007_bib22) 2013; 37
Tek (10.1016/j.jacc.2016.06.007_bib66) 2013; 13
10.1016/j.jacc.2016.06.007_bib78
Shantha (10.1016/j.jacc.2016.06.007_bib102) 2012; 38
Secher (10.1016/j.jacc.2016.06.007_bib19) 2014; 124
Toplak (10.1016/j.jacc.2016.06.007_bib91) 2007; 31
Jefferson (10.1016/j.jacc.2016.06.007_bib74) 2008; 8
Bronstein (10.1016/j.jacc.2016.06.007_bib52) 1993; 60
Suzuki (10.1016/j.jacc.2016.06.007_bib39) 2013; 52
Kast (10.1016/j.jacc.2016.06.007_bib68) 2003; 39
Fonseca (10.1016/j.jacc.2016.06.007_bib35) 2014; 28
Nauck (10.1016/j.jacc.2016.06.007_bib30) 2013; 15
(10.1016/j.jacc.2016.06.007_bib25) 2014
Kahal (10.1016/j.jacc.2016.06.007_bib40) 2015; 15
Sun (10.1016/j.jacc.2016.06.007_bib34) 2015; 2015
Frier (10.1016/j.jacc.2016.06.007_bib33) 2011; 34
Stenlöf (10.1016/j.jacc.2016.06.007_bib90) 2007; 9
Winslow (10.1016/j.jacc.2016.06.007_bib101) 2012; 35
Neter (10.1016/j.jacc.2016.06.007_bib103) 2003; 42
Seino (10.1016/j.jacc.2016.06.007_bib26) 2008; 81
(10.1016/j.jacc.2016.06.007_bib48) 2010
Marso (10.1016/j.jacc.2016.06.007_bib46) 2013; 166
Rothman (10.1016/j.jacc.2016.06.007_bib82) 2001; 39
Garber (10.1016/j.jacc.2016.06.007_bib28) 2009; 373
Pontiroli (10.1016/j.jacc.2016.06.007_bib106) 2013; 50
Chen (10.1016/j.jacc.2016.06.007_bib43) 2016; 52
10.1016/j.jacc.2016.06.007_bib98
Romero-Corral (10.1016/j.jacc.2016.06.007_bib7) 2010; 137
Wilcox (10.1016/j.jacc.2016.06.007_bib69) 2010; 35
Bray (10.1016/j.jacc.2016.06.007_bib87) 2003; 11
Dattilo (10.1016/j.jacc.2016.06.007_bib104) 1992; 56
Garvey (10.1016/j.jacc.2016.06.007_bib100) 2014; 37
Wadden (10.1016/j.jacc.2016.06.007_bib13) 2011; 19
(10.1016/j.jacc.2016.06.007_bib76) 2016
Anderson (10.1016/j.jacc.2016.06.007_bib58) 2002; 10
Sweeting (10.1016/j.jacc.2016.06.007_bib11) 2014; 7
Pi-Sunyer (10.1016/j.jacc.2016.06.007_bib23) 2015; 373
Suter (10.1016/j.jacc.2016.06.007_bib71) 1997; 55
Apovian (10.1016/j.jacc.2016.06.007_bib61) 2013; 21
Nissen (10.1016/j.jacc.2016.06.007_bib80) 2016; 315
James (10.1016/j.jacc.2016.06.007_bib14) 2010; 363
Davies (10.1016/j.jacc.2016.06.007_bib24) 2015; 314
Drew (10.1016/j.jacc.2016.06.007_bib9) 2007; 3
References_xml – year: 2014
  ident: bib64
  publication-title: Contrave [package insert]
– volume: 344
  start-page: d7771
  year: 2012
  ident: bib21
  article-title: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
  publication-title: BMJ
– volume: 55
  start-page: 157
  year: 1997
  end-page: 171
  ident: bib71
  article-title: Effects of alcohol on energy metabolism and body weight regulation: is alcohol a risk factor for obesity?
  publication-title: Nutr Rev
– volume: 5
  start-page: 1218
  year: 2013
  end-page: 1240
  ident: bib5
  article-title: Dyslipidemia in obesity: mechanisms and potential targets
  publication-title: Nutrients
– volume: 2015
  start-page: 157201
  year: 2015
  ident: bib34
  article-title: Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis
  publication-title: J Diabetes Res
– volume: 311
  start-page: 806
  year: 2014
  end-page: 814
  ident: bib1
  article-title: Prevalence of childhood and adult obesity in the United States, 2011–2012
  publication-title: JAMA
– volume: 3
  start-page: 817
  year: 2007
  end-page: 821
  ident: bib9
  article-title: Obesity management: update on orlistat
  publication-title: Vasc Health Risk Manag
– volume: 52
  start-page: 2046
  year: 2009
  end-page: 2055
  ident: bib31
  article-title: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
  publication-title: Diabetologia
– volume: 8
  start-page: 715
  year: 2008
  end-page: 722
  ident: bib74
  article-title: Bupropion extended-release for depressive disorders
  publication-title: Expert Rev Neurother
– volume: 39
  start-page: 32
  year: 2001
  end-page: 41
  ident: bib82
  article-title: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
  publication-title: Synapse
– volume: 56
  start-page: 320
  year: 1992
  end-page: 328
  ident: bib104
  article-title: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
  publication-title: Am J Clin Nutr
– volume: 63
  start-page: 250
  year: 2014
  end-page: 259
  ident: bib3
  article-title: Adipokines: a link between obesity and cardiovascular disease
  publication-title: J Cardiol
– volume: 15
  year: 2013
  ident: bib73
  article-title: Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study
  publication-title: Prim Care Companion CNS Disord
– volume: 374
  start-page: 39
  year: 2009
  end-page: 47
  ident: bib32
  article-title: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
  publication-title: Lancet
– year: 2014
  ident: bib93
  publication-title: Topamax [package insert]
– reference: Qsymia [package insert]. Mountain View, CA: Vivus, Inc.; 2012–2014.
– volume: 15
  start-page: 14
  year: 2015
  ident: bib40
  article-title: The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
  publication-title: BMC Endocr Disord
– volume: 81
  start-page: 161
  year: 2008
  end-page: 168
  ident: bib26
  article-title: Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
  publication-title: Diabetes Res Clin Pract
– volume: 9
  start-page: 544
  year: 2001
  end-page: 551
  ident: bib60
  article-title: Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women
  publication-title: Obes Res
– volume: 34
  start-page: S132
  year: 2011
  end-page: S137
  ident: bib33
  article-title: Hypoglycemia and cardiovascular risks
  publication-title: Diabetes Care
– volume: 37
  start-page: 912
  year: 2014
  end-page: 921
  ident: bib100
  article-title: Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release
  publication-title: Diabetes Care
– volume: 376
  start-page: 595
  year: 2010
  end-page: 605
  ident: bib63
  article-title: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet
– volume: 14
  start-page: 657
  year: 1985
  end-page: 661
  ident: bib55
  article-title: Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men
  publication-title: Brain Res Bull
– year: 2016 Jun 13
  ident: bib47
  article-title: Liraglutide and cardiovascular outcomes in type 2 diabetes
  publication-title: N Engl J Med
– year: 2014
  ident: bib25
  publication-title: Liraglutide (Saxenda) [package insert]
– volume: 60
  start-page: 40
  year: 1993
  end-page: 49
  ident: bib52
  article-title: Pre- and posttranslational regulation of β-endorphin biosynthesis in the CNS: effects of chronic naltrexone treatment
  publication-title: J Neurochem
– year: 2010
  ident: bib84
  publication-title: Phentermine hydrochloride [package insert]
– volume: 39
  start-page: 131
  year: 2003
  end-page: 133
  ident: bib68
  article-title: Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion
  publication-title: J Hepatol
– volume: 30
  start-page: 1480
  year: 2007
  end-page: 1486
  ident: bib89
  article-title: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
  publication-title: Diabetes Care
– reference: Beilfuss L. Orexigen Terminates Required Study for Diet Drug Contrave. Wall Street Journal, May 12, 2015. Available at:
– volume: 52
  start-page: 516
  year: 2016
  end-page: 526
  ident: bib43
  article-title: Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
  publication-title: Endocrine
– volume: 129
  start-page: 2305
  year: 2014
  end-page: 2312
  ident: bib42
  article-title: Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease
  publication-title: Circulation
– volume: 32
  start-page: 343
  year: 2015
  end-page: 352
  ident: bib36
  article-title: Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
  publication-title: Diabet Med
– volume: 35
  start-page: 229
  year: 2010
  end-page: 234
  ident: bib69
  article-title: An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
  publication-title: Addict Behav
– volume: 9
  start-page: 378
  year: 2008
  end-page: 387
  ident: bib37
  article-title: Sibutramine-associated adverse effects: a practical guide for its safe use
  publication-title: Obes Rev
– volume: 9
  start-page: 347
  year: 1985
  end-page: 353
  ident: bib54
  article-title: A controlled trial of naltrexone in obese humans
  publication-title: Int J Obes
– reference: Margulies K, Anstrom KJ, Redfield MM, et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). Paper presented at: American Heart Association Scientific Sessions; November 8, 2015; Orlando, FL.
– volume: 337
  start-page: 602
  year: 1997
  end-page: 606
  ident: bib15
  article-title: Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine
  publication-title: N Engl J Med
– volume: 7
  start-page: 181
  year: 2013
  ident: bib20
  article-title: The central GLP-1: implications for food and drug reward
  publication-title: Front Neurosci
– start-page: CD001867
  year: 2010
  ident: bib72
  article-title: Opioid antagonists for alcohol dependence
  publication-title: Cochrane Database Syst Rev
– volume: 96
  start-page: 243
  year: 2005
  end-page: 251
  ident: bib92
  article-title: Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension
  publication-title: Am J Cardiol
– volume: 124
  start-page: 4473
  year: 2014
  end-page: 4488
  ident: bib19
  article-title: The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
  publication-title: J Clin Invest
– volume: 13
  start-page: 176
  year: 2013
  ident: bib66
  article-title: Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
  publication-title: BMC Psychiatry
– volume: 7
  start-page: 35
  year: 2014
  end-page: 44
  ident: bib11
  article-title: Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate
  publication-title: Diabetes Metab Syndr Obes
– volume: 10
  start-page: 633
  year: 2002
  end-page: 641
  ident: bib58
  article-title: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial
  publication-title: Obes Res
– volume: 84
  start-page: 1
  year: 2014
  end-page: 11
  ident: bib49
  article-title: Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss
  publication-title: Pharmacol Res
– volume: 32
  start-page: 1224
  year: 2009
  end-page: 1230
  ident: bib27
  article-title: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
  publication-title: Diabetes Care
– reference: . Accessed June 13, 2016.
– volume: 36
  start-page: 843
  year: 2012
  end-page: 854
  ident: bib12
  article-title: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
  publication-title: Int J Obes (Lond)
– year: 2010
  ident: bib48
  article-title: FDA Briefing Document NDA 200063 Contrave (Naltrexone 4 mg, 8 mg/Bupropion HCL 90 mg extended release tablet). 2010 Advisory Committee—December 7, 2010
– volume: 110
  start-page: 1060
  year: 2011
  end-page: 1064
  ident: bib105
  article-title: Moderate weight loss improves heart rate variability in overweight and obese adults with type 2 diabetes
  publication-title: J Appl Physiol (1985)
– volume: 31
  start-page: 138
  year: 2007
  end-page: 146
  ident: bib91
  article-title: Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study
  publication-title: Int J Obes (Lond)
– volume: 363
  start-page: 905
  year: 2010
  end-page: 917
  ident: bib14
  article-title: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
  publication-title: N Engl J Med
– volume: 6
  start-page: 209
  year: 2013
  end-page: 216
  ident: bib10
  article-title: Lorcaserin for weight management
  publication-title: Diabetes Metab Syndr Obes
– volume: 28
  start-page: 399
  year: 2014
  end-page: 405
  ident: bib35
  article-title: Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials
  publication-title: J Diabetes Complications
– year: 2016
  ident: bib76
  article-title: Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The LIGHT Study)
  publication-title: ClinicalTrials.gov [Internet]
– volume: 95
  start-page: 297
  year: 2012
  end-page: 308
  ident: bib96
  article-title: Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
  publication-title: Am J Clin Nutr
– volume: 5
  start-page: 262
  year: 2009
  end-page: 269
  ident: bib17
  article-title: Incretin-based therapies for type 2 diabetes mellitus
  publication-title: Nat Rev Endocrinol
– volume: 166
  start-page: 823
  year: 2013
  end-page: 830.e5
  ident: bib46
  article-title: Design of the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial
  publication-title: Am Heart J
– volume: 373
  start-page: 473
  year: 2009
  end-page: 481
  ident: bib28
  article-title: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
  publication-title: Lancet
– volume: 377
  start-page: 1341
  year: 2011
  end-page: 1352
  ident: bib95
  article-title: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
– volume: 42
  start-page: 878
  year: 2003
  end-page: 884
  ident: bib103
  article-title: Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials
  publication-title: Hypertension
– volume: 337
  start-page: 581
  year: 1997
  end-page: 588
  ident: bib16
  article-title: Valvular heart disease associated with fenfluramine-phentermine
  publication-title: N Engl J Med
– volume: 104
  start-page: 92
  year: 2014
  end-page: 96
  ident: bib38
  article-title: Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study
  publication-title: Diabetes Res Clin Pract
– volume: 38
  start-page: 419
  year: 1985
  end-page: 422
  ident: bib57
  article-title: Effects of long-term therapy with naltrexone on body weight in obesity
  publication-title: Clin Pharmacol Ther
– volume: 15
  start-page: 204
  year: 2013
  end-page: 212
  ident: bib30
  article-title: Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
  publication-title: Diabetes Obes Metab
– reference: Silverman E. Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data. Wall Street Journal, March 4, 2015. Available at:
– volume: 35
  start-page: 1529
  year: 2012
  end-page: 1539
  ident: bib101
  article-title: A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults
  publication-title: Sleep
– volume: 100
  start-page: 603
  year: 2015
  end-page: 606
  ident: bib41
  article-title: Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study
  publication-title: J Clin Endocrinol Metab
– volume: 411
  start-page: 480
  year: 2001
  end-page: 484
  ident: bib51
  article-title: Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
  publication-title: Nature
– volume: 314
  start-page: 687
  year: 2015
  end-page: 699
  ident: bib24
  article-title: Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial
  publication-title: JAMA
– volume: 38
  start-page: 417
  year: 2012
  end-page: 426
  ident: bib102
  article-title: Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study
  publication-title: Diabetes Educ
– volume: 28
  start-page: 1399
  year: 2004
  end-page: 1410
  ident: bib88
  article-title: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
  publication-title: Int J Obes Relat Metab Disord
– volume: 37
  start-page: 3309
  year: 2014
  end-page: 3316
  ident: bib99
  article-title: Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
  publication-title: Diabetes Care
– volume: 21
  start-page: 935
  year: 2013
  end-page: 943
  ident: bib61
  article-title: A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
  publication-title: Obesity (Silver Spring)
– volume: 122
  start-page: 3415
  year: 2013
  end-page: 3422
  ident: bib8
  article-title: Inflammation, obesity, and thrombosis
  publication-title: Blood
– volume: 137
  start-page: 711
  year: 2010
  end-page: 719
  ident: bib7
  article-title: Interactions between obesity and obstructive sleep apnea: implications for treatment
  publication-title: Chest
– volume: 19
  start-page: 110
  year: 2011
  end-page: 120
  ident: bib13
  article-title: Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial
  publication-title: Obesity (Silver Spring)
– volume: 16
  start-page: 961
  year: 2000
  end-page: 966
  ident: bib86
  article-title: Influence of topiramate in the regulation of energy balance
  publication-title: Nutrition
– volume: 20
  start-page: 330
  year: 2012
  end-page: 342
  ident: bib94
  article-title: Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)
  publication-title: Obesity (Silver Spring)
– volume: 26
  start-page: S39
  year: 2002
  end-page: S45
  ident: bib6
  article-title: Pathways from obesity to diabetes
  publication-title: Int J Obes Relat Metab Disord
– volume: 10
  start-page: 1049
  year: 2002
  end-page: 1056
  ident: bib59
  article-title: Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms
  publication-title: Obes Res
– volume: 28
  start-page: 302
  year: 2008
  end-page: 307
  ident: bib65
  article-title: A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension
  publication-title: J Clin Psychopharmacol
– volume: 9
  start-page: 360
  year: 2007
  end-page: 368
  ident: bib90
  article-title: Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes
  publication-title: Diabetes Obes Metab
– volume: 165
  start-page: 515
  year: 2008
  end-page: 523
  ident: bib75
  article-title: Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study
  publication-title: Am J Psychiatry
– volume: 33
  start-page: 173
  year: 2008
  end-page: 179
  ident: bib70
  article-title: A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain
  publication-title: Addict Behav
– volume: 116
  start-page: 991
  year: 2015
  end-page: 1006
  ident: bib4
  article-title: Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms
  publication-title: Circ Res
– volume: 35
  start-page: 81
  year: 2015
  end-page: 92
  ident: bib81
  article-title: Treatment of obesity in 2015
  publication-title: J Cardiopulm Rehab Prev
– volume: 8
  start-page: 237
  year: 2011
  end-page: 240
  ident: bib44
  article-title: Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies
  publication-title: Diab Vasc Dis Res
– volume: 125
  start-page: 1290
  year: 2003
  ident: bib67
  article-title: Crohn's disease remission on bupropion
  publication-title: Gastroenterology
– volume: 26
  start-page: 268
  year: 2009
  end-page: 278
  ident: bib29
  article-title: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
  publication-title: Diabet Med
– volume: 8
  start-page: 571
  year: 2005
  end-page: 578
  ident: bib50
  article-title: Anatomy and regulation of the central melanocortin system
  publication-title: Nat Neurosci
– volume: 50
  start-page: 843
  year: 2013
  end-page: 850
  ident: bib106
  article-title: Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet
  publication-title: Acta Diabetol
– volume: 63
  start-page: 2985
  year: 2014
  end-page: 3023
  ident: bib2
  article-title: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
  publication-title: J Am Coll Cardiol
– volume: 21
  start-page: 2163
  year: 2013
  end-page: 2171
  ident: bib97
  article-title: Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
  publication-title: Obesity (Silver Spring)
– volume: 52
  start-page: 1029
  year: 2013
  end-page: 1034
  ident: bib39
  article-title: Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus
  publication-title: Intern Med
– reference: Silverman E. Orexigen Data is 'Unreliable and Premature:' FDA's Jenkins Explains. The Wall Street Journal, March 6, 2015. Available at:
– volume: 94
  start-page: 4898
  year: 2009
  end-page: 4906
  ident: bib56
  article-title: Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo
  publication-title: J Clin Endocrinol Metab
– volume: 315
  start-page: 990
  year: 2016
  end-page: 1004
  ident: bib80
  article-title: Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial
  publication-title: JAMA
– volume: 28
  start-page: 1292
  year: 2003
  end-page: 1299
  ident: bib85
  article-title: Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects
  publication-title: Neuropsychopharmacology
– volume: 37
  start-page: 1443
  year: 2013
  end-page: 1451
  ident: bib22
  article-title: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
  publication-title: Int J Obes (Lond)
– volume: 36
  start-page: 4022
  year: 2013
  end-page: 4029
  ident: bib62
  article-title: Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
  publication-title: Diabetes Care
– volume: 17
  start-page: 30
  year: 2009
  end-page: 39
  ident: bib53
  article-title: Rational design of a combination medication for the treatment of obesity
  publication-title: Obesity (Silver Spring)
– volume: 11
  start-page: 722
  year: 2003
  end-page: 733
  ident: bib87
  article-title: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
  publication-title: Obes Res
– volume: 294
  start-page: E846
  year: 2008
  end-page: E852
  ident: bib18
  article-title: Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
  publication-title: Am J Physiol Endocrinol Metab
– volume: 1
  start-page: 352
  year: 1968
  end-page: 354
  ident: bib83
  article-title: Comparison of continuous and intermittent anorectic therapy in obesity
  publication-title: Br Med J
– volume: 373
  start-page: 11
  year: 2015
  end-page: 22
  ident: bib23
  article-title: A randomized, controlled trial of 3.0 mg of liraglutide in weight management
  publication-title: N Engl J Med
– year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib84
– volume: 110
  start-page: 1060
  year: 2011
  ident: 10.1016/j.jacc.2016.06.007_bib105
  article-title: Moderate weight loss improves heart rate variability in overweight and obese adults with type 2 diabetes
  publication-title: J Appl Physiol (1985)
  doi: 10.1152/japplphysiol.01329.2010
– volume: 8
  start-page: 571
  year: 2005
  ident: 10.1016/j.jacc.2016.06.007_bib50
  article-title: Anatomy and regulation of the central melanocortin system
  publication-title: Nat Neurosci
  doi: 10.1038/nn1455
– volume: 13
  start-page: 176
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib66
  article-title: Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
  publication-title: BMC Psychiatry
  doi: 10.1186/1471-244X-13-176
– volume: 81
  start-page: 161
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib26
  article-title: Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
  publication-title: Diabetes Res Clin Pract
  doi: 10.1016/j.diabres.2008.03.018
– volume: 363
  start-page: 905
  year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib14
  article-title: Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1003114
– volume: 35
  start-page: 229
  year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib69
  article-title: An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
  publication-title: Addict Behav
  doi: 10.1016/j.addbeh.2009.10.017
– volume: 116
  start-page: 991
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib4
  article-title: Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.116.305697
– volume: 10
  start-page: 1049
  year: 2002
  ident: 10.1016/j.jacc.2016.06.007_bib59
  article-title: Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms
  publication-title: Obes Res
  doi: 10.1038/oby.2002.142
– volume: 137
  start-page: 711
  year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib7
  article-title: Interactions between obesity and obstructive sleep apnea: implications for treatment
  publication-title: Chest
  doi: 10.1378/chest.09-0360
– volume: 315
  start-page: 990
  year: 2016
  ident: 10.1016/j.jacc.2016.06.007_bib80
  article-title: Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2016.1558
– volume: 37
  start-page: 3309
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib99
  article-title: Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
  publication-title: Diabetes Care
  doi: 10.2337/dc14-0930
– volume: 373
  start-page: 11
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib23
  article-title: A randomized, controlled trial of 3.0 mg of liraglutide in weight management
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1411892
– volume: 17
  start-page: 30
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib53
  article-title: Rational design of a combination medication for the treatment of obesity
  publication-title: Obesity (Silver Spring)
  doi: 10.1038/oby.2008.461
– volume: 21
  start-page: 935
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib61
  article-title: A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
  publication-title: Obesity (Silver Spring)
  doi: 10.1002/oby.20309
– volume: 14
  start-page: 657
  year: 1985
  ident: 10.1016/j.jacc.2016.06.007_bib55
  article-title: Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men
  publication-title: Brain Res Bull
  doi: 10.1016/0361-9230(85)90115-7
– volume: 32
  start-page: 343
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib36
  article-title: Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
  publication-title: Diabet Med
  doi: 10.1111/dme.12594
– volume: 56
  start-page: 320
  year: 1992
  ident: 10.1016/j.jacc.2016.06.007_bib104
  article-title: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/56.2.320
– volume: 96
  start-page: 243
  year: 2005
  ident: 10.1016/j.jacc.2016.06.007_bib92
  article-title: Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2005.03.053
– volume: 30
  start-page: 1480
  year: 2007
  ident: 10.1016/j.jacc.2016.06.007_bib89
  article-title: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
  publication-title: Diabetes Care
  doi: 10.2337/dc06-2001
– volume: 28
  start-page: 1399
  year: 2004
  ident: 10.1016/j.jacc.2016.06.007_bib88
  article-title: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
  publication-title: Int J Obes Relat Metab Disord
  doi: 10.1038/sj.ijo.0802783
– volume: 104
  start-page: 92
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib38
  article-title: Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study
  publication-title: Diabetes Res Clin Pract
  doi: 10.1016/j.diabres.2014.01.019
– volume: 35
  start-page: 81
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib81
  article-title: Treatment of obesity in 2015
  publication-title: J Cardiopulm Rehab Prev
  doi: 10.1097/HCR.0000000000000112
– volume: 294
  start-page: E846
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib18
  article-title: Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00030.2008
– volume: 374
  start-page: 39
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib32
  article-title: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60659-0
– volume: 124
  start-page: 4473
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib19
  article-title: The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
  publication-title: J Clin Invest
  doi: 10.1172/JCI75276
– year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib48
– start-page: CD001867
  year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib72
  article-title: Opioid antagonists for alcohol dependence
  publication-title: Cochrane Database Syst Rev
– ident: 10.1016/j.jacc.2016.06.007_bib79
– volume: 8
  start-page: 715
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib74
  article-title: Bupropion extended-release for depressive disorders
  publication-title: Expert Rev Neurother
  doi: 10.1586/14737175.8.5.715
– volume: 42
  start-page: 878
  year: 2003
  ident: 10.1016/j.jacc.2016.06.007_bib103
  article-title: Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials
  publication-title: Hypertension
  doi: 10.1161/01.HYP.0000094221.86888.AE
– volume: 36
  start-page: 4022
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib62
  article-title: Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc13-0234
– volume: 100
  start-page: 603
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib41
  article-title: Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2291
– volume: 7
  start-page: 181
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib20
  article-title: The central GLP-1: implications for food and drug reward
  publication-title: Front Neurosci
  doi: 10.3389/fnins.2013.00181
– volume: 32
  start-page: 1224
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib27
  article-title: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
  publication-title: Diabetes Care
  doi: 10.2337/dc08-2124
– volume: 26
  start-page: 268
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib29
  article-title: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
  publication-title: Diabet Med
  doi: 10.1111/j.1464-5491.2009.02666.x
– ident: 10.1016/j.jacc.2016.06.007_bib45
– volume: 411
  start-page: 480
  year: 2001
  ident: 10.1016/j.jacc.2016.06.007_bib51
  article-title: Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
  publication-title: Nature
  doi: 10.1038/35078085
– volume: 165
  start-page: 515
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib75
  article-title: Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2007.07061018
– volume: 39
  start-page: 32
  year: 2001
  ident: 10.1016/j.jacc.2016.06.007_bib82
  article-title: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
  publication-title: Synapse
  doi: 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3
– volume: 31
  start-page: 138
  year: 2007
  ident: 10.1016/j.jacc.2016.06.007_bib91
  article-title: Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study
  publication-title: Int J Obes (Lond)
  doi: 10.1038/sj.ijo.0803382
– volume: 9
  start-page: 347
  year: 1985
  ident: 10.1016/j.jacc.2016.06.007_bib54
  article-title: A controlled trial of naltrexone in obese humans
  publication-title: Int J Obes
– volume: 20
  start-page: 330
  year: 2012
  ident: 10.1016/j.jacc.2016.06.007_bib94
  article-title: Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)
  publication-title: Obesity (Silver Spring)
  doi: 10.1038/oby.2011.330
– volume: 11
  start-page: 722
  year: 2003
  ident: 10.1016/j.jacc.2016.06.007_bib87
  article-title: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
  publication-title: Obes Res
  doi: 10.1038/oby.2003.102
– volume: 84
  start-page: 1
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib49
  article-title: Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2014.04.004
– volume: 28
  start-page: 1292
  year: 2003
  ident: 10.1016/j.jacc.2016.06.007_bib85
  article-title: Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300178
– year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib25
– ident: 10.1016/j.jacc.2016.06.007_bib78
– volume: 3
  start-page: 817
  year: 2007
  ident: 10.1016/j.jacc.2016.06.007_bib9
  article-title: Obesity management: update on orlistat
  publication-title: Vasc Health Risk Manag
– volume: 16
  start-page: 961
  year: 2000
  ident: 10.1016/j.jacc.2016.06.007_bib86
  article-title: Influence of topiramate in the regulation of energy balance
  publication-title: Nutrition
  doi: 10.1016/S0899-9007(00)00452-4
– volume: 122
  start-page: 3415
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib8
  article-title: Inflammation, obesity, and thrombosis
  publication-title: Blood
  doi: 10.1182/blood-2013-05-427708
– volume: 6
  start-page: 209
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib10
  article-title: Lorcaserin for weight management
  publication-title: Diabetes Metab Syndr Obes
  doi: 10.2147/DMSO.S36276
– volume: 19
  start-page: 110
  year: 2011
  ident: 10.1016/j.jacc.2016.06.007_bib13
  article-title: Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial
  publication-title: Obesity (Silver Spring)
  doi: 10.1038/oby.2010.147
– ident: 10.1016/j.jacc.2016.06.007_bib98
– volume: 9
  start-page: 544
  year: 2001
  ident: 10.1016/j.jacc.2016.06.007_bib60
  article-title: Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women
  publication-title: Obes Res
  doi: 10.1038/oby.2001.71
– volume: 34
  start-page: S132
  year: 2011
  ident: 10.1016/j.jacc.2016.06.007_bib33
  article-title: Hypoglycemia and cardiovascular risks
  publication-title: Diabetes Care
  doi: 10.2337/dc11-s220
– volume: 95
  start-page: 297
  year: 2012
  ident: 10.1016/j.jacc.2016.06.007_bib96
  article-title: Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.111.024927
– volume: 377
  start-page: 1341
  year: 2011
  ident: 10.1016/j.jacc.2016.06.007_bib95
  article-title: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60205-5
– volume: 2015
  start-page: 157201
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib34
  article-title: Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis
  publication-title: J Diabetes Res
– volume: 52
  start-page: 1029
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib39
  article-title: Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus
  publication-title: Intern Med
  doi: 10.2169/internalmedicine.52.8961
– volume: 36
  start-page: 843
  year: 2012
  ident: 10.1016/j.jacc.2016.06.007_bib12
  article-title: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
  publication-title: Int J Obes (Lond)
  doi: 10.1038/ijo.2011.158
– volume: 337
  start-page: 581
  year: 1997
  ident: 10.1016/j.jacc.2016.06.007_bib16
  article-title: Valvular heart disease associated with fenfluramine-phentermine
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199708283370901
– volume: 311
  start-page: 806
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib1
  article-title: Prevalence of childhood and adult obesity in the United States, 2011–2012
  publication-title: JAMA
  doi: 10.1001/jama.2014.732
– year: 2016
  ident: 10.1016/j.jacc.2016.06.007_bib76
  article-title: Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The LIGHT Study)
– volume: 94
  start-page: 4898
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib56
  article-title: Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2009-1350
– volume: 39
  start-page: 131
  year: 2003
  ident: 10.1016/j.jacc.2016.06.007_bib68
  article-title: Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(03)00172-7
– volume: 55
  start-page: 157
  year: 1997
  ident: 10.1016/j.jacc.2016.06.007_bib71
  article-title: Effects of alcohol on energy metabolism and body weight regulation: is alcohol a risk factor for obesity?
  publication-title: Nutr Rev
  doi: 10.1111/j.1753-4887.1997.tb06470.x
– volume: 125
  start-page: 1290
  year: 2003
  ident: 10.1016/j.jacc.2016.06.007_bib67
  article-title: Crohn's disease remission on bupropion
  publication-title: Gastroenterology
  doi: 10.1016/j.gastro.2003.02.004
– year: 2016
  ident: 10.1016/j.jacc.2016.06.007_bib47
  article-title: Liraglutide and cardiovascular outcomes in type 2 diabetes
  publication-title: N Engl J Med
– year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib93
– volume: 37
  start-page: 1443
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib22
  article-title: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
  publication-title: Int J Obes (Lond)
  doi: 10.1038/ijo.2013.120
– volume: 52
  start-page: 516
  year: 2016
  ident: 10.1016/j.jacc.2016.06.007_bib43
  article-title: Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
  publication-title: Endocrine
  doi: 10.1007/s12020-015-0798-0
– volume: 166
  start-page: 823
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib46
  article-title: Design of the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2013.07.012
– volume: 15
  start-page: 14
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib40
  article-title: The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
  publication-title: BMC Endocr Disord
  doi: 10.1186/s12902-015-0005-6
– volume: 50
  start-page: 843
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib106
  article-title: Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet
  publication-title: Acta Diabetol
  doi: 10.1007/s00592-013-0454-1
– volume: 5
  start-page: 262
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib17
  article-title: Incretin-based therapies for type 2 diabetes mellitus
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2009.48
– volume: 9
  start-page: 378
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib37
  article-title: Sibutramine-associated adverse effects: a practical guide for its safe use
  publication-title: Obes Rev
  doi: 10.1111/j.1467-789X.2007.00425.x
– volume: 52
  start-page: 2046
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib31
  article-title: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
  publication-title: Diabetologia
  doi: 10.1007/s00125-009-1472-y
– volume: 373
  start-page: 473
  year: 2009
  ident: 10.1016/j.jacc.2016.06.007_bib28
  article-title: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)61246-5
– volume: 38
  start-page: 419
  year: 1985
  ident: 10.1016/j.jacc.2016.06.007_bib57
  article-title: Effects of long-term therapy with naltrexone on body weight in obesity
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.1985.197
– volume: 314
  start-page: 687
  year: 2015
  ident: 10.1016/j.jacc.2016.06.007_bib24
  article-title: Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial
  publication-title: JAMA
  doi: 10.1001/jama.2015.9676
– volume: 8
  start-page: 237
  year: 2011
  ident: 10.1016/j.jacc.2016.06.007_bib44
  article-title: Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies
  publication-title: Diab Vasc Dis Res
  doi: 10.1177/1479164111408937
– volume: 376
  start-page: 595
  year: 2010
  ident: 10.1016/j.jacc.2016.06.007_bib63
  article-title: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60888-4
– volume: 26
  start-page: S39
  year: 2002
  ident: 10.1016/j.jacc.2016.06.007_bib6
  article-title: Pathways from obesity to diabetes
  publication-title: Int J Obes Relat Metab Disord
  doi: 10.1038/sj.ijo.0802126
– volume: 7
  start-page: 35
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib11
  article-title: Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate
  publication-title: Diabetes Metab Syndr Obes
– volume: 129
  start-page: 2305
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib42
  article-title: Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.113.006985
– volume: 28
  start-page: 302
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib65
  article-title: A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/JCP.0b013e318172424e
– year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib64
– volume: 38
  start-page: 417
  year: 2012
  ident: 10.1016/j.jacc.2016.06.007_bib102
  article-title: Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study
  publication-title: Diabetes Educ
  doi: 10.1177/0145721712443293
– volume: 1
  start-page: 352
  year: 1968
  ident: 10.1016/j.jacc.2016.06.007_bib83
  article-title: Comparison of continuous and intermittent anorectic therapy in obesity
  publication-title: Br Med J
  doi: 10.1136/bmj.1.5588.352
– volume: 63
  start-page: 250
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib3
  article-title: Adipokines: a link between obesity and cardiovascular disease
  publication-title: J Cardiol
– volume: 15
  start-page: 204
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib30
  article-title: Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.12012
– volume: 63
  start-page: 2985
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib2
  article-title: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.11.004
– volume: 60
  start-page: 40
  year: 1993
  ident: 10.1016/j.jacc.2016.06.007_bib52
  article-title: Pre- and posttranslational regulation of β-endorphin biosynthesis in the CNS: effects of chronic naltrexone treatment
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1993.tb05820.x
– volume: 33
  start-page: 173
  year: 2008
  ident: 10.1016/j.jacc.2016.06.007_bib70
  article-title: A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain
  publication-title: Addict Behav
  doi: 10.1016/j.addbeh.2007.05.012
– volume: 9
  start-page: 360
  year: 2007
  ident: 10.1016/j.jacc.2016.06.007_bib90
  article-title: Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2006.00618.x
– volume: 344
  start-page: d7771
  year: 2012
  ident: 10.1016/j.jacc.2016.06.007_bib21
  article-title: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
  publication-title: BMJ
  doi: 10.1136/bmj.d7771
– volume: 15
  issue: 3
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib73
  article-title: Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study
  publication-title: Prim Care Companion CNS Disord
– volume: 37
  start-page: 912
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib100
  article-title: Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release
  publication-title: Diabetes Care
  doi: 10.2337/dc13-1518
– volume: 28
  start-page: 399
  year: 2014
  ident: 10.1016/j.jacc.2016.06.007_bib35
  article-title: Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials
  publication-title: J Diabetes Complications
  doi: 10.1016/j.jdiacomp.2014.01.009
– volume: 337
  start-page: 602
  year: 1997
  ident: 10.1016/j.jacc.2016.06.007_bib15
  article-title: Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199708283370904
– volume: 10
  start-page: 633
  year: 2002
  ident: 10.1016/j.jacc.2016.06.007_bib58
  article-title: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial
  publication-title: Obes Res
  doi: 10.1038/oby.2002.86
– volume: 5
  start-page: 1218
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib5
  article-title: Dyslipidemia in obesity: mechanisms and potential targets
  publication-title: Nutrients
  doi: 10.3390/nu5041218
– volume: 21
  start-page: 2163
  year: 2013
  ident: 10.1016/j.jacc.2016.06.007_bib97
  article-title: Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
  publication-title: Obesity (Silver Spring)
  doi: 10.1002/oby.20584
– volume: 35
  start-page: 1529
  year: 2012
  ident: 10.1016/j.jacc.2016.06.007_bib101
  article-title: A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults
  publication-title: Sleep
  doi: 10.5665/sleep.2204
– ident: 10.1016/j.jacc.2016.06.007_bib77
SSID ssj0006819
Score 2.326898
SecondaryResourceType review_article
Snippet The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well...
AbstractThe global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 849
SubjectTerms Anti-Obesity Agents - pharmacology
Cardiology
Cardiovascular
cardiovascular disease
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
FDA approval
Health risk assessment
Humans
Life Style
Low density lipoprotein
Obesity
Obesity - complications
Obesity - drug therapy
pharmacology
prevention
Risk Factors
risk factors
Title Cardiovascular Effects of the New Weight Loss Agents
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0735109716335471
https://www.clinicalkey.es/playcontent/1-s2.0-S0735109716335471
https://dx.doi.org/10.1016/j.jacc.2016.06.007
https://www.ncbi.nlm.nih.gov/pubmed/27539178
https://www.proquest.com/docview/1814349445
https://www.proquest.com/docview/1812884513
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VHhAXxKPQhVIZqbcq3fgZ51hWVBUCLrTq3izHD6lVtVs12yu_nbHjBFWUInFMMiMnk_F4xp75BuAg_WZ0O3hVOxUqEZmorIhdpT1trQ00oZSlbIvv6vRcfFnK5RYsxlqYlFZZbP9g07O1LnfmRZrzm8vL-Q9UTkkzBBLnUuQ6ci50LuJbfpqssdK5uUcirhJ1KZwZcryurEswhlRlDM_UUvbhxelvzmdehE5ewPPiPZLj4QVfwlZYvYKn38r5-GsQi3vppWTAJu7JOhJ09AhaNHKR90LJVxyfHKe6qn4Hzk8-ny1Oq9IXoXKirTf4GZG3QSUcFuYddayTwemolJde1Fx43XW2jdF3UQamMcBzmtrGS8WZa63jb2B7tV6FXSBNZLX31tIG1-pgrcboB31EZqNyXkU5AzoKxLgCGp56V1ybMTvsyiQhmiREk1PkmhkcTjw3A2TGo9R8lLMZi0HRfBm06I9yNQ9xhb7MwN5Q0zNTmz-0ZAZy4rynaP8ccW9UAvN7EI3upmiFQEF9nB7jBE2nLnYV1neZhmktJOUzeDsozyQWhsEixsv63X--1Ht4lq7SHjfje7C9ub0LH9BJ2nT78OToJ93Pc-EX-S8MCw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgGXijcLpRiJGwobP-McqxXVFra90IreLMcPqRXarZrtld_OjONsVVGKxDX2yMlkZjxjz3xDyEf8zeB2iKr2OlYycVk5mbrKBNY6FxmilGG2xbGen8qvZ-psi8zGWhhMqyy2f7Dp2VqXJ9PCzenl-fn0OwinYhkCSQglsY78gQT1Re38_Osmz0Ob3N0DZ1c4vVTODEleF84jjiHTGcQTe8revTv9zfvMu9DBE7JT3Ee6P7zhU7IVl8_Iw6NyQf6cyNmt_FI6gBP3dJUoeHoUTBr9kQ9D6QLWp_tYWNW_IKcHX05m86o0Rqi8bOs1fEYSbdQIxMKDZ553KnqTtA4qyFrIYLrOtSmFLqnIDUR43jDXBKUF963z4iXZXq6W8TWhTeJ1CM6xBjbr6JyB8AecRO6S9kEnNSFsZIj1BTUcm1f8tGN62IVFJlpkos05cs2EfNrQXA6YGffOFiOf7VgNCvbLgkm_l6q5iyr2RQV7y2zPbW3_EJMJURvKW5L2zxV3RyGwN4sY8DdlKyUw6sNmGDQUr13cMq6u8xxujFRMTMirQXg2bOEQLULAbN7850u9J4_mJ0cLuzg8_vaWPMYRPPDmYpdsr6-u4zvwmNbdXtaI3wuJDh8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiovascular+Effects+of+the+New+Weight+Loss+Agents&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Vorsanger%2C+Matthew+H.&rft.au=Subramanyam%2C+Pritha&rft.au=Weintraub%2C+Howard+S.&rft.au=Lamm%2C+Steven+H.&rft.date=2016-08-23&rft.issn=0735-1097&rft.volume=68&rft.issue=8&rft.spage=849&rft.epage=859&rft_id=info:doi/10.1016%2Fj.jacc.2016.06.007&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jacc_2016_06_007
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F07351097%2FS0735109716X00289%2Fcov150h.gif